Tirzepatide has received three FDA approvals: Mounjaro for type 2 diabetes (May 2022), Zepbound for obesity (November 2023), and Zepbound for obstructive sleep apnea (June 2024). A cardiovascular outcomes indication is under investigation. Here is the complete tirzepatide FDA approval timeline, approved doses, and what comes next.
Tirzepatide is FDA approved under two brand names: Mounjaro (type 2 diabetes, May 2022) and Zepbound (obesity, November 2023; obstructive sleep apnea, June 2024). A cardiovascular outcomes indication is currently under investigation via the SURMOUNT-MMO trial.
Tirzepatide's dual GLP-1/GIP receptor agonism mechanism has enabled approvals across multiple metabolic indications. Each approval was supported by Phase 3 clinical evidence from Eli Lilly's SURPASS (diabetes) and SURMOUNT (obesity/metabolic) trial programs.
| Brand | Indication | Approval Date | Key Clinical Data |
|---|---|---|---|
| Mounjaro | Type 2 Diabetes | May 13, 2022 | HbA1c reduction of 1.87–2.59% vs 0.86–1.97% for semaglutide (SURPASS-2) |
| Zepbound | Chronic Weight Management (Obesity) | November 8, 2023 | 22.5% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg dose) |
| Zepbound | Obstructive Sleep Apnea | June 2024 | 63% reduction in apnea-hypopnea index (SURMOUNT-OSA) |
First-in-human studies. Safety, tolerability, and pharmacokinetics established in healthy volunteers and T2D patients.
Dose-ranging in T2D patients. Established the 5 mg, 10 mg, 15 mg dose ladder. Strong HbA1c and weight reduction signals.
SURPASS 1–5: tirzepatide vs placebo, semaglutide, insulin degludec, and insulin glargine. All primary endpoints met.
FDA approved tirzepatide (Mounjaro) for type 2 diabetes. Breakthrough Therapy designation granted. Priority Review.
SURMOUNT-1: 22.5% mean weight loss at 72 weeks vs 2.4% placebo (p<0.001). SURMOUNT-2: T2D with obesity, 15.7% weight loss.
FDA approved tirzepatide (Zepbound) for chronic weight management. First dual GLP-1/GIP agonist approved for obesity.
FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug approved for this indication.
SURMOUNT-MMO: cardiovascular outcomes trial in adults with obesity without T2D. Estimated completion 2026. Potential CV indication approval 2027.
A common source of confusion is that Mounjaro and Zepbound are the same medication — tirzepatide — at the same doses, manufactured by the same company (Eli Lilly). The FDA requires separate approvals for separate indications, which is why tirzepatide has two brand names. The practical difference for patients is primarily insurance coverage: Mounjaro is covered by most insurance plans for type 2 diabetes, while Zepbound coverage for obesity-only patients is more variable and often requires prior authorization.
Off-label use for weight loss is common but not covered by insurance for obesity-only patients.
Eligible if BMI ≥30 or ≥27 with a weight-related condition (hypertension, T2D, dyslipidemia, sleep apnea).
The FDA-approved titration schedule for tirzepatide starts at 2.5 mg once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated. The approved maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5 mg and 7.5 mg doses are titration steps only. Slower titration (every 6–8 weeks) is commonly used off-label to reduce nausea during dose escalation.
| Week | Dose | Step Type | Notes |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg/wk | Initiation | Starting dose only — not a maintenance dose |
| Weeks 5–8 | 5 mg/wk | Titration / Maintenance | First maintenance dose; some patients stay here long-term |
| Weeks 9–12 | 7.5 mg/wk | Titration | Titration step only — not a maintenance dose |
| Weeks 13–16 | 10 mg/wk | Titration / Maintenance | Second maintenance dose option |
| Weeks 17–20 | 12.5 mg/wk | Titration | Titration step only — not a maintenance dose |
| Week 21+ | 15 mg/wk | Maximum Maintenance | Maximum approved dose; highest efficacy (22.5% weight loss in SURMOUNT-1) |
Eli Lilly is pursuing additional FDA approvals for tirzepatide beyond the three current indications. The most advanced is the cardiovascular outcomes indication, supported by the SURMOUNT-MMO trial. A positive cardiovascular outcomes result would make tirzepatide the first obesity drug with a proven long-term cardiovascular benefit — a significant milestone for the drug class.
Primary endpoint: reduction in major adverse cardiovascular events (MACE) in adults with obesity without T2D. If positive, would be the first obesity drug with proven CV benefit.
Liver fibrosis and NASH resolution endpoints. GLP-1/GIP agonism has shown strong liver fat reduction in earlier trials.
Renal outcomes data from SURPASS-CVOT showed promising kidney protection signals. Dedicated CKD trial not yet announced.
| Agent | FDA Status | Approved Indications | Mean Weight Loss | Mechanism |
|---|---|---|---|---|
| Semaglutide | Approved | T2D (2017), Obesity (2021), CV risk (2023) | ~15% | GLP-1 agonist |
| Tirzepatide | Approved | T2D (2022), Obesity (2023), Sleep Apnea (2024) | ~22.5% | GLP-1 + GIP dual agonist |
| Retatrutide | Phase 3 | Not yet approved — est. 2027–2028 | ~24% (Phase 2) | GLP-1 + GIP + Glucagon triple agonist |
Yes. Tirzepatide has two FDA-approved brand names: Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management in adults with obesity or overweight with a weight-related condition). Both are manufactured by Eli Lilly and contain the same active ingredient — tirzepatide — at the same doses.
Mounjaro and Zepbound contain identical active ingredients (tirzepatide) at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes management (blood sugar control), while Zepbound is approved for chronic weight management (obesity). Insurance coverage differs significantly between the two — Zepbound coverage for obesity is more limited than Mounjaro coverage for T2D.
Tirzepatide (Mounjaro) was first FDA approved on May 13, 2022, for adults with type 2 diabetes as an adjunct to diet and exercise to improve blood sugar control. Tirzepatide (Zepbound) received a second FDA approval on November 8, 2023, for chronic weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² with at least one weight-related condition such as hypertension or dyslipidemia.
The FDA-approved tirzepatide titration schedule starts at 2.5 mg once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, up to a maximum dose of 15 mg once weekly. The maintenance doses are 5 mg, 10 mg, and 15 mg. The 2.5 mg and 7.5 mg doses are titration doses only and are not intended as long-term maintenance doses.
As of April 2026, Eli Lilly has submitted or is preparing submissions for additional tirzepatide indications including: (1) cardiovascular outcomes reduction in adults with obesity (SURMOUNT-MMO trial data), (2) obstructive sleep apnea (SURMOUNT-OSA trial, positive results), and (3) non-alcoholic steatohepatitis (NASH/MASH). The sleep apnea indication received FDA approval in June 2024, making tirzepatide the first drug approved for obesity-related sleep apnea.
Research-grade tirzepatide is available from verified suppliers like Purgo Labs for research purposes only. This is distinct from the FDA-approved prescription medications Mounjaro and Zepbound, which require a prescription from a licensed healthcare provider. Research-grade tirzepatide from Purgo Labs comes with third-party COAs confirming ≥99% purity.
Semaglutide (Ozempic/Wegovy) was FDA approved for T2D in 2017 and for obesity in 2021. Tirzepatide (Mounjaro/Zepbound) was approved for T2D in 2022 and obesity in 2023. Retatrutide is not yet FDA approved — it is in Phase 3 trials with an estimated approval date of 2027–2028. Tirzepatide's dual GLP-1/GIP mechanism produces ~22% weight loss vs ~15% for semaglutide, and retatrutide's triple agonism (GLP-1/GIP/glucagon) produced ~24% in Phase 2 trials.
Purgo Labs provides pharmaceutical-grade tirzepatide with third-party COAs from accredited US labs confirming ≥99% purity. Use code HEALTH for 15% off your first order.
Shop Purgo LabsUse code HEALTH for 15% off · Research use only
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.